- Home
- Publications
- Publication Search
- Publication Details
Title
Empagliflozin prevents doxorubicin-induced myocardial dysfunction
Authors
Keywords
-
Journal
Cardiovascular Diabetology
Volume 19, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-15
DOI
10.1186/s12933-020-01040-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
- (2019) Chenguang Li et al. Cardiovascular Diabetology
- SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice
- (2019) Damilola D. Adingupu et al. Cardiovascular Diabetology
- The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
- (2019) Hsiang-Chun Lee et al. Cardiovascular Diabetology
- Sodium–glucose co‐transporter 2 inhibition with empagliflozin improves cardiac function in non‐diabetic rats with left ventricular dysfunction after myocardial infarction
- (2019) Salva R. Yurista et al. EUROPEAN JOURNAL OF HEART FAILURE
- Empagliflozin Attenuates Myocardial Sodium and Calcium Dysregulation and Reverses Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats
- (2019) Ting-I Lee et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Cardiac ischemia–reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity
- (2019) Akira Yoshii et al. Cardiovascular Diabetology
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Calcitriol Attenuates Doxorubicin-Induced Cardiac Dysfunction and Inhibits Endothelial-to-Mesenchymal Transition in Mice
- (2019) Tsai et al. Cells
- Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats
- (2019) Qingmiao Shao et al. Cardiovascular Diabetology
- Inhibition of miR-296-5p protects the heart from cardiac hypertrophy by targeting CACNG6
- (2019) Wei Wang et al. GENE THERAPY
- Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
- (2018) Karin Rådholm et al. CIRCULATION
- Transcoronary concentration gradients of circulating microRNAs in heart failure
- (2018) Salvatore De Rosa et al. EUROPEAN JOURNAL OF HEART FAILURE
- Contemporary Role of Echocardiography for Clinical Decision Making in Patients During and After Cancer Therapy
- (2018) Jennifer Liu et al. JACC-Cardiovascular Imaging
- Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes
- (2018) Kwong-Man Ng et al. Scientific Reports
- A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats
- (2018) Aysegul Durak et al. Cardiovascular Diabetology
- MicroRNA-296-5p promotes healing of diabetic wound by targeting sodium-glucose transporter 2 (SGLT2)
- (2018) Xiaomin Liu et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study
- (2017) Geeta Gulati et al. Journal of the American Heart Association
- Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure
- (2017) Milton Packer et al. JAMA Cardiology
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
- (2016) Antonius Baartscheer et al. DIABETOLOGIA
- Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus
- (2016) Nikolaus Marx et al. EUROPEAN HEART JOURNAL
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
- (2016) David Fitchett et al. EUROPEAN HEART JOURNAL
- Sodium–glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis
- (2016) Harindra Rajasekeran et al. KIDNEY INTERNATIONAL
- Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking
- (2016) Carmela Coppola et al. OncoTargets and Therapy
- Angiotensin II–Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer
- (2016) Annelies H. Boekhout et al. JAMA Oncology
- Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy
- (2015) Lu Fang et al. Journal of Translational Medicine
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protective effects of spironolactone against anthracycline-induced cardiomyopathy
- (2014) Mahmut Akpek et al. EUROPEAN JOURNAL OF HEART FAILURE
- Prevention of Anthracycline-Induced Cardiotoxicity
- (2014) Pimprapa Vejpongsa et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Wilcoxon's signed-rank statistic: what null hypothesis and why it matters
- (2014) Heng Li et al. PHARMACEUTICAL STATISTICS
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
- (2013) A. Schneeweiss et al. ANNALS OF ONCOLOGY
- Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
- (2013) C. S. Kovacs et al. DIABETES OBESITY & METABOLISM
- Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis
- (2013) Kashif Kalam et al. EUROPEAN JOURNAL OF CANCER
- Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101 - Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI
- (2011) Edith Pituskin et al. BMC CANCER
- Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Cardiotoxicity
- (2010) I. Brana et al. ANNALS OF ONCOLOGY
- Functional effects of glucose transporters in human ventricular myocardium
- (2010) Dirk von Lewinski et al. EUROPEAN JOURNAL OF HEART FAILURE
- Women survive breast cancer but fall victim to heart failure: the shadows and lights of targeted therapy
- (2010) Nicola Maurea et al. Journal of Cardiovascular Medicine
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started